XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Related-Party Transactions
 6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions
(12)
Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of June 30, 2022, Ginkgo owned 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At June 30, 2022, the Company had remaining balances of $1.7 million and $7.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. The Company used $1.2 million and $1.7 million of the pre-paid research and development expenses for the three and six months ended June 30, 2022.